Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | PGR | P06401 | 3/20 | 0.43 |
| ▸ | B3GNT2 | Q9NY97 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | PDE2A | O00408 | 4/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.37 |
| ▸ | CBX7 | O95931 | 1/20 | 0.37 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.37 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.37 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850384 | 0.90 | MAOB (0.42) | MAOBLMNAPDE2APDE3BPDE3A | |
| SCHEMBL27611288 | 0.87 | HSD17B3 (0.45) | MAOBPGRB3GNT2LMNAKDM4E | |
| SCHEMBL8546016 | 0.80 | LMNA (0.44) | MAOBPGRLMNAKDM4EALDH1A1 | |
| SCHEMBL30593445 | 0.80 | LMNA (0.46) | MAOBPGRB3GNT2LMNACBX7 | |
| SCHEMBL21156822 | 0.80 | LMNA (0.46) | MAOBPGRB3GNT2LMNACBX7 | |
| SCHEMBL4859467 | 0.79 | SMN1; SMN2 (0.55) | LMNACYP2D6KDM4EALDH1A1MEN1 | |
| SCHEMBL6035441 | 0.77 | TP53 (0.44) | MAOBPGRLMNADRD1HIF1A | |
| Hydrochloric Acid SCHEMBL4861258 | 0.76 | TP53 (0.44) | MAOBPGRLMNAHIF1AMAPT | |
| SCHEMBL21156818 | 0.76 | LMNA (0.51) | MAOBPGRB3GNT2LMNAMEN1 | |
| SCHEMBL1759132 | 0.76 | B3GNT2 (0.61) | MAOBPGRB3GNT2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | MAOB 248/4885PGR 4161/4885B3GNT2 787/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | MAOB 248/4885PGR 4161/4885B3GNT2 787/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | MAOB 108/4885PGR 3759/4885B3GNT2 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.